JP2008044931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008044931A5 JP2008044931A5 JP2007182717A JP2007182717A JP2008044931A5 JP 2008044931 A5 JP2008044931 A5 JP 2008044931A5 JP 2007182717 A JP2007182717 A JP 2007182717A JP 2007182717 A JP2007182717 A JP 2007182717A JP 2008044931 A5 JP2008044931 A5 JP 2008044931A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- pharmaceutical composition
- dementia
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 31
- 208000035475 disorder Diseases 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 10
- 230000004770 neurodegeneration Effects 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 206010012335 Dependence Diseases 0.000 claims 5
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 230000036651 mood Effects 0.000 claims 5
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010061428 decreased appetite Diseases 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 235000019577 caloric intake Nutrition 0.000 claims 2
- 229960003920 cocaine Drugs 0.000 claims 2
- 230000001143 conditioned effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 230000003880 negative regulation of appetite Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 231100000572 poisoning Toxicity 0.000 claims 2
- 230000000607 poisoning effect Effects 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 201000001716 specific phobia Diseases 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000004260 weight control Methods 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000022372 Reading disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010043903 Tobacco abuse Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 238000011292 agonist therapy Methods 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83089006P | 2006-07-14 | 2006-07-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008044931A JP2008044931A (ja) | 2008-02-28 |
| JP2008044931A5 true JP2008044931A5 (enExample) | 2008-10-02 |
| JP4312243B2 JP4312243B2 (ja) | 2009-08-12 |
Family
ID=38542082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007182717A Expired - Fee Related JP4312243B2 (ja) | 2006-07-14 | 2007-07-12 | （７Ｓ）−７−［（５−フルオロ−２−メチル−ベンジル）オキシ］−２−［（２Ｒ）−２−メチルピペラジン−１−イル］−６，７−ジヒドロ−５Ｈ−シクロペンタ［ｂ］ピリジンの酒石酸塩 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100004259A1 (enExample) |
| EP (1) | EP2044029B1 (enExample) |
| JP (1) | JP4312243B2 (enExample) |
| KR (1) | KR20090029299A (enExample) |
| CN (1) | CN101506172A (enExample) |
| AR (1) | AR062068A1 (enExample) |
| AT (1) | ATE496894T1 (enExample) |
| AU (1) | AU2007274710A1 (enExample) |
| CA (1) | CA2657640A1 (enExample) |
| DE (1) | DE602007012254D1 (enExample) |
| IL (1) | IL196417A0 (enExample) |
| MX (1) | MX2009000508A (enExample) |
| NO (1) | NO20090667L (enExample) |
| TW (1) | TW200821293A (enExample) |
| WO (1) | WO2008010073A1 (enExample) |
| ZA (1) | ZA200901051B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
| JP5124308B2 (ja) | 2008-02-26 | 2013-01-23 | 株式会社リコー | トナー、該トナーを用いた現像剤、トナー入り容器、プロセスカートリッジ、及び画像形成方法 |
| WO2010079605A1 (ja) * | 2009-01-09 | 2010-07-15 | 東レ・ファインケミカル株式会社 | 高純度１－ベンジル－３－アミノピロリジンの製造方法 |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| US9993273B2 (en) | 2013-01-16 | 2018-06-12 | Mako Surgical Corp. | Bone plate and tracking device using a bone plate for attaching to a patient's anatomy |
| US9566120B2 (en) | 2013-01-16 | 2017-02-14 | Stryker Corporation | Navigation systems and methods for indicating and reducing line-of-sight errors |
| US10095785B2 (en) * | 2013-09-30 | 2018-10-09 | Sonos, Inc. | Audio content search in a media playback system |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US10606822B2 (en) * | 2014-11-01 | 2020-03-31 | Hewlett Packard Enterprise Development Lp | Dynamically updating metadata |
| US10537395B2 (en) | 2016-05-26 | 2020-01-21 | MAKO Surgical Group | Navigation tracker with kinematic connector assembly |
| RU2762896C2 (ru) | 2016-12-20 | 2021-12-23 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин |
| CA3047354A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| AU2018299824B2 (en) * | 2017-07-11 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Novel substituted xanthine derivatives |
| CN110958876B (zh) | 2018-06-20 | 2020-12-18 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| WO2023248222A1 (en) * | 2022-06-21 | 2023-12-28 | Technion Research & Development Foundation Limited | 5-ht2c receptor modulating agents for the treatment of neurodegenerative, mental, cognitive and autoimmune cns disorders |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| US5019574A (en) * | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
| DE4326151A1 (de) * | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
| TW270114B (enExample) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
| US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
| US6040448A (en) * | 1997-10-24 | 2000-03-21 | Neurogen Corporation | Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands |
| RU2198873C2 (ru) * | 1998-02-26 | 2003-02-20 | Акцо Нобель Н.В. | Производные азетидина и пирролидина |
| GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| GB9819019D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| EP1109544A4 (en) * | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE |
| GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
| US6465467B1 (en) * | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| WO2001054907A1 (de) * | 2000-01-25 | 2001-08-02 | Koenig & Bauer Aktiengesellschaft | Bogendruckmaschine mit siebdruckzylinder |
| EP1152407A3 (en) * | 2000-04-25 | 2006-10-25 | Matsushita Electric Industrial Co., Ltd. | Optical disk, method for producing the same, and apparatus for producing the same |
| SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| PT1385823E (pt) * | 2001-04-09 | 2007-01-31 | Novartis Vaccines & Diagnostic | Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4) |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| JP4449746B2 (ja) * | 2002-07-12 | 2010-04-14 | アステラス製薬株式会社 | Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体 |
| US7183413B2 (en) * | 2003-04-11 | 2007-02-27 | Taigen Biotechnology | Aminoquinoline compounds |
| US7101881B2 (en) * | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
| US20070015771A1 (en) * | 2004-07-29 | 2007-01-18 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| JP4318744B2 (ja) * | 2005-03-31 | 2009-08-26 | ファイザー・プロダクツ・インク | シクロペンタピリジンおよびテトラヒドロキノリン誘導体 |
-
2007
- 2007-07-09 EP EP07735013A patent/EP2044029B1/en not_active Not-in-force
- 2007-07-09 CA CA002657640A patent/CA2657640A1/en not_active Abandoned
- 2007-07-09 AU AU2007274710A patent/AU2007274710A1/en not_active Abandoned
- 2007-07-09 AT AT07735013T patent/ATE496894T1/de not_active IP Right Cessation
- 2007-07-09 DE DE602007012254T patent/DE602007012254D1/de active Active
- 2007-07-09 MX MX2009000508A patent/MX2009000508A/es unknown
- 2007-07-09 CN CNA2007800316816A patent/CN101506172A/zh active Pending
- 2007-07-09 WO PCT/IB2007/002025 patent/WO2008010073A1/en not_active Ceased
- 2007-07-09 KR KR1020097002844A patent/KR20090029299A/ko not_active Ceased
- 2007-07-12 JP JP2007182717A patent/JP4312243B2/ja not_active Expired - Fee Related
- 2007-07-13 AR ARP070103136A patent/AR062068A1/es not_active Application Discontinuation
- 2007-07-13 TW TW096125659A patent/TW200821293A/zh unknown
-
2008
- 2008-01-24 US US12/373,774 patent/US20100004259A1/en not_active Abandoned
-
2009
- 2009-01-08 IL IL196417A patent/IL196417A0/en unknown
- 2009-02-11 NO NO20090667A patent/NO20090667L/no not_active Application Discontinuation
- 2009-02-13 ZA ZA200901051A patent/ZA200901051B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008044931A5 (enExample) | ||
| JP2008534568A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| NZ600008A (en) | Multicyclic compounds and methods of use thereof | |
| JP2013512926A5 (enExample) | ||
| RU2009139285A (ru) | Производные тиазолидина в качестве антагонистов рецептора орексина | |
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| JP2007516941A5 (enExample) | ||
| JP2010520265A5 (enExample) | ||
| JP2009538867A5 (enExample) | ||
| WO2007085556A3 (en) | Use of 4-imidazole derivatives for cns disorders | |
| JP2016508142A5 (enExample) | ||
| JP2004527467A5 (enExample) | ||
| RU2005101748A (ru) | Новые хинуклидиновые производные и их применение | |
| FI2841431T4 (fi) | Bentsotiofeeniyhdisteen dihydraatti ja menetelmä sen tuottamiseksi | |
| EA200970310A1 (ru) | Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht | |
| UA105187C2 (uk) | Похідне 7-піперидиналкіл-3,4-дигідрохінолону | |
| CA2602348A1 (en) | Cyclopentapyridine and tetrahydroquinoline derivatives | |
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| WO2009038752A3 (en) | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses | |
| WO2009023126A3 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| TW200745135A (en) | Therapeutic agents | |
| JP2005517036A5 (enExample) | ||
| JP2008526706A5 (enExample) |